Brief: Shenzhen Neptunus Interlong Bio-Technique Says Ribavirin Product Added To Treatment Plans Of Coronavirus
06/02/2020 15:02
Feb 6 (Reuters) - Shenzhen Neptunus Interlong Bio-technique
Co Ltd 8329.HK :
* UNIT'S RIBAVIRIN PRODUCT ADDED TO TREATMENT PLANS OF
PNEUMONIA
CAUSED BY NOVEL CORONAVIRUS
Source text for Eikon: ID:nHKS1scSBY
Further company coverage: 8329.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Neptunus Interlong Bio-technique
See all newsBrief: Shenzhen Neptunus Interlong Bio-Technique's Unit Enters Into JV Agreement With Huikang Bio-Technology
China's Neptunus Interlong H1 revenue falls
Brief: Shenzhen Neptunus Interlong Bio-Technique Expects Net Profit Attributable To Owners Of RMB 7 Million For 2026 Interim Period
Brief: Shenzhen Neptunus Interlong Bio-Technique Posts FY Loss & Total Comprehensive Expenses Attributable RMB40.7 Million
Brief: Shenzhen Neptunus Interlong Bio-Technique Sees FY Net Loss Attributable Of RMB40 Million